Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life‐threatening thrombotic microangiopathy (TMA), characterized by disseminated thrombus formation in the microvasculature, causing severe organ failure. Immune‐mediated TTP is occasionally described after vaccination, especially against viral agents. We report a case of a 38‐year old woman with a de novo iTTP after exposure to the mRNA‐based anti‐COVID‐19 vaccine produced by Pfizer‐BioNTech. She presented with increased bruising and petechiae, starting 2 weeks after receiving the first dose of the anti‐COVID‐19 vaccine. Laboratory data revealed a severe ADAMTS13‐deficiency in combination with a very high autoantibody titer against ADAMTS13. She was successfully treated with plasma exchange, corticosteroids, rituximab and Caplacizumab. To our knowledge, this is the first case report of iTTP post mRNA‐based COVID‐19‐vaccination in a previously TTP‐naïve patient.